menu
    • menu

    Company profile for 3M Company

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    HTL Biotechnology is a French biotech & a global leader in the responsible development & production of pharma-grade biopolymers.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    EXCIPIENTS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    3M Health Information Systems and another health care industry solution vendor, provider or payer organizations. By integrating or embedding our tools and content into your solutions, we can help you increase the value of your solutions and reduce your development and delivery costs. 3M touches virtually every part of your life. Our people and technology make the impossible, possible. Every day we apply our science to enhance...
    3M Health Information Systems and another health care industry solution vendor, provider or payer organizations. By integrating or embedding our tools and content into your solutions, we can help you increase the value of your solutions and reduce your development and delivery costs. 3M touches virtually every part of your life. Our people and technology make the impossible, possible. Every day we apply our science to enhance people’s lives. This is 3M Science. Applied to Life.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    3M CompanyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    3M CenterBuilding 275-03-E-10St. Paul, MN 55144-1000
    Telephone
    Telephone
    +(1) 800-643-8086
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.3m.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/3m/
    youtube
    YouTube
    Twitter
    Twitter
    https://x.com/3M

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    INTERVIEW #SpeakPharma

    [Sponsored by another company]
    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    “Translational Pharmaceutics, our flagship platform for drug development, empowers our clients with unparalleled flexibility”

    This week, SpeakPharma interviews Denise Sutton, Chief Operating Officer and Site Head at Quotient Sciences’ Nottingham facility in the UK. Quotient Sciences is a drug development and manufacturing accelerator that offers the innovative Translational Pharmaceutics platform to support customers in overcoming drug development challenges. Sutton has been with the company for over 25 years. In this interview, she provides insights into the evolution of Quotient Sciences’ Nottingham facility and discusses how the organization has transformed from a small 10-bed clinic to a comprehensive drug development campus with six GMP suites. She also shares her perspective on the company’s unique approach to integrating drug development services. HIGHLIGHTS// evolution of Quotient Sciences’ Nottingham facility/ unique approach to integrating drug development services How has the Nottingham site transformed from when it was founded, to what it is today? Initially, we were a small company with fewer than 50 employees, a 10-bed clinic, and a single lab. Over 90 percent of our work focused on gamma scintigraphic imaging (a diagnostic test that creates images of the body’s internal organs and tissues using gamma rays). Due to the short half-life radionuclides we used to label dosage forms, every product we manufactured had a limited time to be dosed. At the end of 1999, we moved our headquarters to a purpose-built, two-storey facility—now known as Trent House on our now much larger Nottingham campus. We built three good manufacturing practice (GMP) suites on the top floor and three clinical wards on the bottom floor. These were very early days that marked the start of our Translational Pharmaceutics platform. We continued to expand the range of scintigraphy applications we offered in response to changing customer requirements until, in 2008, when we approached the MHRA (UK’s Medicines and Healthcare products Regulatory Agency) with a new request. We asked if it might be possible to work at the same pace as we did in our scintigraphic imaging studies, but do so for conventional drug development, without the radiolabel. We explored the application of ICH Q8 Quality by Design (QbD) guidelines to introduce a compositional design space into the CMC section of our regulatory dossier. This officially created a methodology for applying the Translational Pharmaceutics platform, and we haven't looked back since. Today, we have expanded substantially. Our Nottingham site is a campus of five buildings. We have development and analytical labs, six GMP suites, six clinical wards with a total of 85 beds (where we conduct healthy volunteer phase 1 clinical studies), and many talented colleagues covering our spectrum of CRO and CDMO services. HIGHLIGHTS// officially created a methodology for applying the Translational Pharmaceutics platform/ development and analytical labs/ six GMP suites   How is Translational Pharmaceutics applied to drug development programs? We apply Translational Pharmaceutics across three core applications: first-in-human clinical studies, drug product optimization programs through rapid formulation development and clinical testing, and as a part of human ADME (absorption, distribution, metabolism, and excretion) programs. No matter how a client chooses to work with us to apply Translational Pharmaceutics, the benefits of using a single organization and project management team to integrate services lets our clients remain in control and one step ahead of the emerging data that impacts the success of their molecule. Over all these years, our flagship Translational Pharmaceutics platform for drug development has remained unchanged in the way it empowers our customers and offers them unparalleled flexibility. HIGHLIGHTS// three core applications/ benefits of using a single organization/ clients remain in control   What would you say are the key strengths of Quotient Sciences’ Nottingham site? How do you support customer programs? Nowhere else would a single project manager oversee such a broad spectrum of activities, let alone be expected to ensure seamless, timely progression across functions that in any other company (i.e. at other CDMOs or CROs) would be delivered through multiple operating areas or through the use of a combination of third-party vendors. The project managers do face challenges. But by working with the project team, they are able to anticipate, avoid, and mitigate any impact whenever necessary. We know that time is incredibly valuable for our customers. A project Gantt chart is our project management team’s guiding light. I believe our project management team is truly world-leading – they communicate well, show great compassion, and lead with integrity. I’m super proud of our high-performing, supportive, cross-functional teams that support our customers when they trust their molecules to us, and work collaboratively to deliver the best possible service. After 25 years at Quotient, I continue to really enjoy going to work. I am indebted to various colleagues for helping me continue to feel this way. HIGHLIGHTS// project management team is truly world-leading/ high-performing, supportive, cross-functional teams/ 25 years at Quotient  

    Impressions: 5476

    subscribeSubscribe

    https://www.pharmacompass.com/speak-pharma/translational-pharmaceutics-our-flagship-platform-for-drug-development-empowers-our-clients-with-unparalleled-flexibility

    Radio Compass
    16 Dec 2024
    Share info Share

    VLOG #PharmaReel

    [Sponsored by another company]

    DATA COMPILATION #PharmaFlow

    [Sponsored by another company]
    Top first-in-class drug candidates of 2025: Ionis’ donidalorsen, Sanofi’s fitusiran, Cytokinetics’ aficamten await FDA approval

    Top first-in-class drug candidates of 2025: Ionis’ donidalorsen, Sanofi’s fitusiran, Cytokinetics’ aficamten await FDA approval

    First‑in‑class drugs are therapies with entirely new approaches that improve patient outcomes and fundamentally change treatment paradigms.This week, PharmaCompass brings a compilation of 2025’s most promising first-in-class drug candidates. With their US Food and Drug Administration (FDA) action dates in 2025, many of these drugs, once approved, hold the potential of becoming blockbusters.Ionis’ donidalorsen, Sanofi’s fitusiran, Cytokinetics’ aficamten poised to transform patient careIonis’ donidalorsen is an exciting candidate designed to tackle hereditary angioedema (HAE), a rare condition marked by unpredictable and potentially life‑threatening swelling episodes.This novel antisense oligonucleotide works by “silencing” the messenger RNA that codes for prekallikrein — a protein that triggers inflammation leading to swelling. Instead of blocking a protein once it’s made, donidalorsen stops the cell from producing it in the first place. This precision approach could mean fewer infusions and reduced side effects compared to traditional treatments.Another promising candidate is Sanofi and Alnylam Pharmaceuticals’ fitusiran. It employs the technology of small interfering RNA (siRNA) to lower levels of antithrombin — a natural protein that, when in excess, can impair the blood’s ability to clot. By reducing antithrombin, fitusiran rebalances the blood’s clotting process in patients with hemophilia A and B.Similarly, Cytokinetics’ aficamten is designed to treat obstructive hypertrophic cardiomyopathy (oHCM), a condition in which the heart muscle becomes abnormally thick, obstructing blood flow. Aficamten works by inhibiting cardiac myosin, a protein that drives heart muscle contraction. This helps relieve symptoms like shortness of breath and chest pain. If approved, aficamten is expected to rake in annual sales of US$ 2.8 billion by 2030.UroGen, J&J’s candidates eye US$ 5 bn markets; AbbVie, Summit’s meds target lung cancerUroGen Pharma’s UGN‑102 is poised to redefine the treatment of non‑muscle‑invasive bladder cancer. This innovative formulation uses a reverse thermal gel technology that transforms from a liquid into a gel once inside the bladder. This change ensures that the chemotherapeutic agent, mitomycin, remains in contact with the bladder lining for a longer period, increasing its effectiveness at eradicating cancer cells and reducing the risk of recurrence.For patients, UGN‑102 could mean a non‑surgical, outpatient treatment option that is less invasive than traditional surgical methods. If approved, UGN-102 could address a US market of approximately 82,000 patients annually, translating into a market opportunity exceeding US$ 5 billion, according to company estimates.Johnson & Johnson’s nipocalimab is a new treatment aimed at helping people with autoimmune diseases — a group of conditions where the body’s defense system mistakenly attacks its own healthy cells. Nipocalimab works by blocking the neonatal Fc receptor (FcRn), thereby lowering the levels of pathogenic antibodies that drive many autoimmune disorders. J&J had acquired this FcRn blocker in 2020 as part of its US$ 6.5 billion takeover of Momenta Pharmaceuticals. J&J is trialing the drug in as many as 10 indications and expects peak annual sales in excess of US$ 5 billion.AbbVie’s antibody-drug conjugate (ADC), telisotuzumab vedotin, is designed as a “guided-missile” to deliver toxic drugs directly to cancer cells while sparing healthy tissues. Telisotuzumab vedotin targets c‑Met, a receptor that is over-expressed in certain cancers such as non‑small cell lung cancer (NSCLC). There are currently no approved anti-cancer therapies specifically for c-Met over-expressing NSCLC.Summit Therapeutics’ ivonescimab is a cutting‑edge bispecific antibody designed specifically for NSCLC. Unlike traditional therapies that target a single molecule, ivonescimab binds simultaneously to a tumor-specific antigen on cancer cells and to a receptor on T cells, effectively bringing these two together so the body’s own immune system can recognize and attack the tumor. This dual engagement strategy helps overcome common mechanism tumors.Insmed’s Brensocatib is an innovative, first‐in‐class oral inhibitor of dipeptidyl peptidase‑1 (DPP‑1) that targets a key step in the inflammatory cascade. DPP‑1 is responsible for activating neutrophil serine proteases — enzymes that, when overactive, can cause significant lung tissue damage in conditions such as non‑cystic fibrosis bronchiectasis. Brensocatib is expected to clock annual sales of US$ 2.8 billion by 2030.Gepotidacin, an investigational antibiotic developed by GSK, is poised to make a significant impact in the treatment of uncomplicated urinary tract infections (uUTIs) and urogenital gonorrhea. If approved, it would be the first oral antibiotic in a new class for uUTIs in over two decades.Arrowhead, Regenxbio, Ultragenyx address rare, genetic diseasesArrowhead Pharmaceuticals is developing an innovative gene-targeting therapy — plozasiran. This drug uses RNA interference (RNAi) to interrupt the gene responsible for producing apolipoprotein C‑III (APOC3), a protein that regulates blood triglyceride levels. For people with severe hypertriglyceridemia or familial chylomicronemia syndrome (FCS) — a severe and rare genetic disease for which there are currently no FDA‑approved treatments — high triglyceride levels can lead to pancreatitis and other serious cardiovascular issues. Regenxbio’s RGX‑121 is a one‑time gene therapy candidate for Hunter syndrome (MPS 2), a rare, inherited disorder that causes progressive neurological decline. The therapy uses a harmless virus to deliver a functional copy of the gene encoding iduronate‑2‑sulfatase (I2S) directly into the central nervous system. By restoring the missing enzyme, RGX‑121 aims to slow or even reverse the harmful buildup of substances in the brain that drive the disease’s progression.Another promising candidate is Ultragenyx Pharmaceuticals’ one-time intravenous gene therapy UX111 for Sanfilippo syndrome type A (MPS 3A). This devastating disorder, which leads to severe neurodegeneration in children, currently has no effective treatment. UX111 uses an adeno‑associated virus (AAV) to deliver a working copy of the SGSH gene, the deficiency of which is responsible for the disease. By enabling the body to produce the missing enzyme, UX111 holds the promise of slowing or even halting the progression of neurodegeneration.Our viewThis year has already seen several first-in-class approvals, such as Vertex’s suzetrigine (Journavx), a pioneering non‐opioid analgesic redefining pain management; SpringWorks’ mirdametinib (Gomekli), a breakthrough MEK inhibitor for a genetic disorder that often leads to the growth of benign tumors along nerves and; AstraZeneca and Daiichi’s ADC datopotamab deruxtecan (Datroway).Despite the volatile political environment in the US and its impact on federal agencies like the FDA, we are hopeful that many of the first-in-class drugs mentioned in this article will make a debut in 2025. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3527

    https://www.pharmacompass.com/radio-compass-blog/top-first-in-class-drug-candidates-of-2025-ionis-donidalorsen-sanofi-s-fitusiran-cytokinetics-aficamten-await-fda-approval

    #Phispers by PHARMACOMPASS
    27 Feb 2025
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    3M plans to spin out $8.5B healthcare division into its own company
    3M plans to spin out $8.5B healthcare division into its own company

    03 Aug 2022

    // Tyler Patchen ENDPTS

    https://endpts.com/3m-plans-to-spin-out-8-5b-healthcare-division-into-its-own-company/

    Tyler Patchen ENDPTS
    03 Aug 2022
    Share Share
    3M, Qiagen to comply with Biden's COVID-19 vaccination, test mandate
    3M, Qiagen to comply with Biden's COVID-19 vaccination, test mandate

    10 Sep 2021

    // REUTERS

    https://www.reuters.com/article/us-health-coronavirus-mandate/3m-qiagen-to-comply-with-bidens-covid-19-vaccination-test-mandate-idUSKBN2G61PR

    REUTERS
    10 Sep 2021
    Share Share
    3M Canada Company Recalls Vanish
    3M Canada Company Recalls Vanish

    03 Oct 2017

    // HEALTH CANADA

    https://www.pharmacompass.com/pdf/news/3m-canada-company-recalls-vanish-1507097481.pdf

    HEALTH CANADA
    03 Oct 2017
    Share Share
    3M Canada Company Recalls Peridex Oral Rinse
    3M Canada Company Recalls Peridex Oral Rinse

    29 Jun 2017

    // HEALTH CANADA

    https://www.pharmacompass.com/pdf/news/3m-canada-company-recalls-peridex-oral-rinse-1498797095.pdf

    HEALTH CANADA
    29 Jun 2017
    Share Share
    3M Canada Company Issues Recall Of SoluPrep QD Swab Due To The Affected Lot is Labelled With an Incorrect Lot Number
    3M Canada Company Issues Recall Of SoluPrep QD Swab Due To The Affected Lot is Labelled With an Incorrect Lot Number

    20 Apr 2017

    // HEALTH CANADA

    https://www.pharmacompass.com/pdf/news/3m-canada-company-issues-recall-of-soluprep-qd-swab-due-to-the-affected-lot-is-labelled-with-an-incorrect-lot-number-1492663121.pdf

    HEALTH CANADA
    20 Apr 2017
    Share Share
    Lonza Confirms Interest in Capsugel Takeover
    Lonza Confirms Interest in Capsugel Takeover

    13 Dec 2016

    // G MacDonald IN PHARMATECHNOLOGIST

    http://www.in-pharmatechnologist.com/Drug-Delivery/Lonza-confirms-interest-in-Capsugel-takeover

    G MacDonald IN PHARMATECHNOLOGIST
    13 Dec 2016
    Share Share

    USDMF

    read-more
    read-more

    01

    Adrenaline (epinephrine) And Salts O...

    U.S.A
    Natural Products Expo
    Not Confirmed
    arrow

    02

    Adrenalone Hydrochloride

    U.S.A
    Natural Products Expo
    Not Confirmed
    arrow

    03

    Betafine® Pleated Polyprolylene Car...

    U.S.A
    Natural Products Expo
    Not Confirmed
    arrow

    04

    Betapure Nt-p Series Cartridge Produ...

    U.S.A
    Natural Products Expo
    Not Confirmed
    arrow

    05

    Ci-1017 Transdermal Delivery System

    U.S.A
    Natural Products Expo
    Not Confirmed
    arrow

    06

    Climara Pro(r) Estradiol/levonorgest...

    U.S.A
    Natural Products Expo
    Not Confirmed
    arrow

    07

    Cordran (flurandrenolide) Tape

    U.S.A
    Natural Products Expo
    Not Confirmed
    arrow

    08

    Drospirenone/ethinyl Estradiol Trans...

    U.S.A
    Natural Products Expo
    Not Confirmed
    arrow

    09

    Estradiol Transdermal Drug Delivery ...

    U.S.A
    Natural Products Expo
    Not Confirmed
    arrow

    10

    Isoprenaline (isoproterenol) And Its...

    U.S.A
    Natural Products Expo
    Not Confirmed
    arrow
    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    3M Adjuvant Boosts Immune Response to Plant-Based COVID-19 Vaccine in Thailand Clinical Trials

    Details:

    Baiya’s SARS-CoV-2 Vax 2 is second-generation plant-produced vaccine modelled on prototype SARS-CoV-2 RBD antigen adjuvanted with 3M-052-AF-alum. Data from first cohort of 12 participants demonstrated no significant changes in vital signs during first 120 min of observation.


    Lead Product(s): 25 Baiya SARS-CoV-2 Vax 2

    Therapeutic Area: Infections and Infectious Diseases Brand Name: Undisclosed

    Study Phase: Phase IProduct Type: Vaccine

    Recipient: Baiya Phytopharm

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 29, 2022

    blank

    01

    3M Company

    U.S.A
    arrow
    Natural Products Expo
    Not Confirmed

    3M Company

    U.S.A
    arrow
    Natural Products Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 25 Baiya SARS-CoV-2 Vax 2

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Recipient : Baiya Phytopharm

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    3M Adjuvant Boosts Immune Response to Plant-Based COVID-19 Vaccine in Thailand Clinical Trials

    Details : Baiya’s SARS-CoV-2 Vax 2 is second-generation plant-produced vaccine modelled on prototype SARS-CoV-2 RBD antigen adjuvanted with 3M-052-AF-alum. Data from first cohort of 12 participants demonstrated no significant changes in vital signs during first ...

    Product Name : Undisclosed

    Product Type : Vaccine

    Upfront Cash : Not Applicable

    September 29, 2022

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Deals
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    New Adjuvanted Vaccine Candidate Using IDRI Formulation Demonstrates Coronavirus Pan-Vaccine Potential

    Details:

    Vaccine candidate, which combines a nanoparticle developed by a Duke-led research team with IDRI’s novel formulation of 3M’s “3M-052” compound Produced more “broadly neutralizing antibodies” against several strains of coronavirus, including bat coronaviruses.


    Lead Product(s): 3M-052,Potassium Alum

    Therapeutic Area: Infections and Infectious Diseases Brand Name: 3M-052

    Study Phase: PreclinicalProduct Type: Vaccine

    Sponsor: IDRI

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Collaboration May 03, 2021

    blank

    02

    3M Company

    U.S.A
    arrow
    Natural Products Expo
    Not Confirmed

    3M Company

    U.S.A
    arrow
    Natural Products Expo
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : 3M-052,Potassium Alum

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Preclinical

    Partner/Sponsor/Collaborator : IDRI

    Deal Size : Undisclosed

    Deal Type : Collaboration

    DEALS_DEV arrow-down

    New Adjuvanted Vaccine Candidate Using IDRI Formulation Demonstrates Coronavirus Pan-Vaccine Poten...

    Details : Vaccine candidate, which combines a nanoparticle developed by a Duke-led research team with IDRI’s novel formulation of 3M’s “3M-052” compound Produced more “broadly neutralizing antibodies” against several strains of coronavirus, including b...

    Product Name : 3M-052

    Product Type : Vaccine

    Upfront Cash : Undisclosed

    May 03, 2021

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Excipients

    Click here to find the perfect excipient manufacturers by their capabilities

    Inspections and registrations

    Upload your audits for free, ask us

    ABOUT THIS PAGE

    Contact 3M Company and get a quotation

    3M Company is a supplier offers 48 products (APIs, Excipients or Intermediates).

    Find a price of Betaine bulk with DMF offered by 3M Company

    Find a price of Phosgene bulk with DMF offered by 3M Company

    Find a price of FLURANDRENOLIDE DRUG-IN-ADHESIVE R-2813 bulk with DMF offered by 3M Company

    Find a price of LIFEASSURE(TM) PFS SERIES AND LIFEASSURE(TM) FP SERIES FILTER PRODUCTS bulk with DMF offered by 3M Company

    Find a price of 3M™ EMPHAZE AEX HYBRID PURIFIER, 3M™ POLISHER ST AND 3M™ HARVEST RC & 3M™ HARVEST RC CENTRATE CHROMATOPGRAPHIC CLARIFIER bulk with DMF offered by 3M Company

    Find a price of ZETA PLUS™ AP, CA, CP HP, HTP, HTM, LA, LP, LPM, M, SA, SP, VR, Z, ZB, ZA AND DELIPID PRODUCT SERIES bulk with DMF offered by 3M Company

    Find a price of ZETAPOR™ NYLON MEMBRANE CARTRIDGE PRODUCTS: LIFEASSURE PSA SERIES, LIFEASSURE BLA SERIES, LIFEASSURE PLA SERIES, LIFEASSURE 020S4, 045SP, 020SP, AND 020ST SERIES, AND LIFEASSURE MEMBRANE DISC PRODUCTS bulk with DMF offered by 3M Company

    Find a price of LIFEASSURE™ PDA AND PNA SERIES FILTER PRODUCTS bulk with DMF offered by 3M Company

    Find a price of Adrenalone bulk offered by 3M Company

    Find a price of Epinephrine bulk offered by 3M Company

    Find a price of Flecainide bulk offered by 3M Company

    Find a price of Isoproterenol Hydrochloride bulk offered by 3M Company

    Find a price of Methenamine Hippurate bulk offered by 3M Company

    Find a price of Orphenadrine bulk offered by 3M Company

    Find a price of Perfluorodichlorooctane bulk offered by 3M Company

    Find a price of PIRBUTEROL ACETATE bulk offered by 3M Company

    Find a price of Polyurethane Y-290 bulk offered by 3M Company

    Find a price of Resiquimod bulk offered by 3M Company

    Find a price of Salsalate bulk offered by 3M Company

    Find a price of Testosterone bulk offered by 3M Company

    Find a price of ZETA PLUS DELIPID PLUS bulk offered by 3M Company

    Find a price of FACILITIES, PERSONNEL AND PROCED. IN PITHIVIERS, CEDEX, FRANCE bulk offered by 3M Company

    Find a price of ZETA PLUS DELIPID FILTER MEDIUM (DEL3 FORMULATION) bulk offered by 3M Company

    Find a price of TRANSDERMAL PATCH A-81418 bulk offered by 3M Company

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES BY 3M NEOTECHNIC LIMITED IN LEICESTERSHIRE, ENGLAND. bulk offered by 3M Company

    Find a price of FOR CORDOVA,ILLINOIS bulk offered by 3M Company

    Find a price of MFG. SITE,LOUGHBOROUGH,ENGLAND bulk offered by 3M Company

    Find a price of LIFEASSURE PFC SERIES FILTERS bulk offered by 3M Company

    Find a price of ZETACARBON RX5S, SP AND SLP SERIES bulk offered by 3M Company

    Find a price of TRANSDERMAL PATCH LY188035 bulk offered by 3M Company

    Find a price of ZETA PLUS M SERIES GRADED DENSITY MEDIA AND CARTIDGE PRODUCTS bulk offered by 3M Company

    Find a price of ZETAPOR 020ST bulk offered by 3M Company

    Find a price of FACILITIES FOR MFG OF TRANSDERMAL DELIVERY DRUG PRODUCTS bulk offered by 3M Company

    Find a price of ZETACARBON R.1SP AND SLP SERIES bulk offered by 3M Company

    Find a price of FOR BROOKINGS,S.D. bulk offered by 3M Company

    Find a price of INVESTIGATIONAL NEW DRUG PROCEDURES bulk offered by 3M Company

    Find a price of GAMMA IRRADIATION FACILITY LOCATED IN EDE, THE NETHERLANDS bulk offered by 3M Company

    Find a price of ZETA PLUS VIRAL REMOVAL MEDIA bulk offered by 3M Company

    Find a price of MANUFACTURING AND CONTROL FACILITIES AND PERSONNEL bulk offered by 3M Company

    Find a price of VARIOUS RAUWOLFIA SPECIES bulk offered by 3M Company

    Find a price of ZETA PLUS DELIPID FILTER MEDIUM (DEL2 FORMULATION) bulk offered by 3M Company

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES OF SPUNLACED FABRIC TAPE IN BROOKINGS, SD. bulk offered by 3M Company

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN THRONLEIGH NSW, AUSTRALIA. bulk offered by 3M Company

    Find a price of MANUFACTURE AND ASSEMBLY FACILITIES bulk offered by 3M Company

    Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN RAMAT-GAN, ISRAEL. bulk offered by 3M Company

    Find a price of PERSONNEL,FACILITIES AND GEN.OPERATING PROCEDURES DECATUR ALABAMA bulk offered by 3M Company

    Find a price of BIOLIFE(TM) FILTER PRODUCTS bulk offered by 3M Company

    Find a price of ZETA PLUS CA,LA,SA,ZA, SERIES bulk offered by 3M Company

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search